News
The day at a glance · 4 min read
Mood · Cautious
+15
Sentiment, −100 to +100
Merck Pipeline Value
$70B
Big Pharma Dealmaking & Pipeline
Point-of-Care Diagnostics Market 2026
$20.63B
MedTech & Diagnostics
Point-of-Care Diagnostics Market 2031
$31.46B+8.8% CAGR
MedTech & Diagnostics
Key driverDeal activity from Lilly-QurCan genetic medicine partnership and Pfizer ADC licensing balanced by Abbott's recall settlement and mixed analyst views
Daily briefHealthcare· Money365.Market AI ·

Healthcare M&A, Pipeline Updates Drive Wednesday Session

Lilly inks genetic medicine deal, Abbott settles formula recall, J&J posts stronger lung cancer survival data

Big Pharma Dealmaking & Pipeline

Bullish
LLYPFEMRKAMGNGILD
Eli Lilly (LLY) signed a genetic medicine deal with QurCan, under which QurCan will optimize genetic therapeutics using its technology while Lilly oversees further research and commercialization. An analyst adjusted estimates for the company following its weight-loss business surge, with one fast-growing business potentially pushing results above guidance.
Pfizer (PFE) signed a co-development and license deal with Medicus Pharma for an early clinical-stage CD228-targeting antibody-drug conjugate. The agreement grants Medicus exclusive global rights to develop and commercialize the CD228V candidate across multiple human disease areas, while Pfizer retains economic participation through financial milestones, royalties and ongoing involvement in the development program. Pfizer's prostate cancer treatment Xtandi was highlighted in prostate cancer awareness coverage alongside clinical-stage programs from Candel and Janux.
Merck (MRK) deepened its innovation push through a new clinical trial collaboration in which Perspective Therapeutics will test its targeted alpha therapy [212Pb]PSV359 with Merck's immunotherapy Keytruda in certain FAP-expressing lung and colorectal cancers. The company's $70 billion pipeline was profiled, with one analysis describing a powerful drug pipeline fueling a stock trend that ranks in the top 6% of US stocks worth more than $1 billion, though noting the ticket price for investors is steep and the clock is ticking on its biggest asset.
Amgen (AMGN) outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a Morgan Stanley conference, with newly appointed Chief Financial Officer Thomas Dittrich emphasizing execution, financial discipline and cash-on-cash returns. The company highlighted MariTide and IMDELLTRA pipeline progress.
Gilead Sciences (GILD) executives outlined plans to expand the company's HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O'Day describing the company as being at an inflection point in value. The company sees Yeztugo powering HIV growth as its oncology pipeline advances.

Clinical Trial Data & Oncology

Bullish
JNJ
Johnson & Johnson (JNJ) reported new clinical trial results for RYBREVANT-based regimens in EGFR-mutated NSCLC at a major oncology conference. The Phase 2b COPERNICUS study showed RYBREVANT plus LAZCLUZE for newly diagnosed patients with EGFR-mutated NSCLC had improved tolerability and fewer treatment-related adverse events. Final data from the Phase 3 PAPILLON trial found first-line RYBREVANT plus chemotherapy produced the longest reported median overall survival in EGFR exon 20 mutations.
Novartis saw its prostate cancer treatment Pluvicto spotlighted in prostate cancer awareness coverage alongside clinical-stage programs from Candel and Janux.

MedTech & Diagnostics

Neutral

Boston Scientific Trailing Price/Sales

3.2x
ISRGABTBSX
Intuitive Surgical (ISRG) received the world's first CE mark for transvaginal gynecologic procedures using its da Vinci SP system. The approval expands the da Vinci SP platform's labeled use in Europe to include transvaginal access for gynecologic surgery, positioning Intuitive Surgical as an early mover in single port, natural orifice gynecologic procedures in the region.
The global point-of-care diagnostics market is projected to grow from $20.63 billion in 2026 to $31.46 billion by 2031, at an 8.8% CAGR. Growth is driven by demand for rapid, accurate and decentralized testing, alongside advances in molecular diagnostics, microfluidics, multiplex assays and portable analyzers. Biochemistry holds the largest technology share, while molecular diagnostics and infectious disease testing are set for strong growth, with clinical laboratories leading by end user. Key players profiled include QuidelOrtho, Sysmex, HemoCue, Trinity Biotech and Abbott Laboratories (ABT).
Boston Scientific (BSX) stock was analyzed following a 57% decline over the past year, to about $45. The shares now sell for 3.2 times trailing sales, hovering near their decade-long historical trough of roughly 3.0 times and well off their peak.

Abbott Formula Recall Settlement

$385M
ABT
Abbott Laboratories (ABT) reached a $385 million settlement tied to the 2022 infant formula recall and Sturgis plant shutdown. The agreement resolves civil claims from families, states, and other plaintiffs alleging product safety failures and gaps in compliance with federal standards. The settlement follows U.S. Department of Justice and multi-state investigations into Abbott's infant formula operations, with no admission of liability.

Analyst Activity & Leadership Changes

Bullish

Wolfe Biogen/AbbVie Price Target

$300

Thermo Fisher 2028 Organic Growth Target

7%
BIIBABBVTMO
Wolfe Research upgraded Biogen (BIIB) and AbbVie (ABBV) to Outperform from Peer Perform on August 13, assigning both companies similar $300 price targets. The firm's logic in each case was based on a comparable set of factors: pipelines that the market appears to undervalue.
Legend Biotech's new CEO Ingrid Zhang most recently served as chief commercial officer for Novartis International, paving the way for buyout speculation according to one analysis.
Thermo Fisher Scientific (TMO) CEO Marc Casper said in a CNBC interview that AI is helping drugmakers identify ineffective medicines quicker while also shortening the time to market for promising therapies. Casper sees AI driving more pharma spending and projects 7% organic growth by 2028.

Managed Care

Neutral
UNH
UnitedHealth Group (UNH) announced it will release its third quarter 2026 financial results on Tuesday, October 13, 2026, before the market opens.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy